A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia

Trial Profile

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2014

At a glance

  • Drugs MK 0557 (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 04 Nov 2008 Trial end date changed from Nov 2008 to Oct 2008 as reported by Clinicaltrials.gov.
    • 04 Nov 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Sep 2008 Planned end date changed from 1 Aug 2008 to 1 Nov 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top